Scinai Immunotherapeutics Files October 6-K Report

TL;DR

Scinai Immunotherapeutics filed its October 6-K, confirming its foreign private issuer status and principal office in Israel.

AI Summary

Scinai Immunotherapeutics Ltd. (formerly BiondVax Pharmaceuticals Ltd.) filed a Form 6-K on October 15, 2024. This report is for the month of October 2024 and indicates the company is a foreign private issuer filing under the 1934 Act. The company's principal executive office is located in Jerusalem, Israel.

Why It Matters

This filing provides an update on Scinai Immunotherapeutics' regulatory reporting status as a foreign private issuer. Investors should monitor these filings for any material changes or disclosures.

Risk Assessment

Risk Level: low — This filing is a routine report of a foreign private issuer and does not contain specific financial or operational disclosures that would immediately indicate high risk.

Key Players & Entities

• Scinai Immunotherapeutics Ltd. (company) — Registrant
• BiondVax Pharmaceuticals Ltd. (company) — Former company name
• October 15, 2024 (date) — Filing date
• Jerusalem, Israel (location) — Principal executive office

FAQ

From the Filing

0001213900-24-087739.txt : 20241015 0001213900-24-087739.hdr.sgml : 20241015 20241015153359 ACCESSION NUMBER: 0001213900-24-087739 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 5 CONFORMED PERIOD OF REPORT: 20241015 FILED AS OF DATE: 20241015 DATE AS OF CHANGE: 20241015 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Scinai Immunotherapeutics Ltd. CENTRAL INDEX KEY: 0001611747 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37353 FILM NUMBER: 241371617 BUSINESS ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 BUSINESS PHONE: 972-8-9302529 MAIL ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: BiondVax Pharmaceuticals Ltd. DATE OF NAME CHANGE: 20140624 6-K 1 ea0217508-6k_scinai.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________ FORM 6-K _______________ Report of Foreign Private Issuer Pursuant to Rule 13a -16 or 15d -16 Under the Securities Exchange Act of 1934 For the Month of October 2024 Commission File Number: 001 -37353 _______________ SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) _______________ Jerusalem BioPark, 2 nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel (Address of principal executive office) _______________ Indicate by check mark whether the registrant files or will file annual reports under cover Form 20 -F or Form 40 -F . Form 20 -F ☒             Form 40 -F ☐   Explanatory Note Scinai Immunotherapeutics Ltd. (the “Company”) is scheduling an Annual Meeting of Shareholders on Thursday, November 21, 2024, at 4:00 p.m. Israel time at the offices of Goldfarb Gross Seligman & Co., One Azrieli Center, Round Tower, Tel Aviv, Israel (the “Meeting”). The Company hereby furnishes the following documents with respect to the Meeting: (1)      Notice and Proxy Statement with respect to the Meeting, describing the proposals to be voted upon at the Meeting, the procedure for voting in person or by proxy at the Meeting and various other details related to the Meeting; and (2)      Proxy Card whereby holders of the Company’s American Depositary Shares may vote at the meeting without attending in person. The Notice and Proxy Statement is furnished with this Form 6 -K  as Exhibit 99.1 and the Proxy Card is furnished with this Form 6 -K  as Exhibit 99.2 This Report on Form 6 -K  is hereby incorporated by reference into the registrant’s Registration Statements on Form S -8  (File No.  333 -271293  and File No.  333 -239344 ) and Form F -3  (File No.  333 -274078  and File No.  333 -276767 ), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. Exhibit Index Exhibit No.   Description 99.1   Notice and Proxy Statement of Annual Meeting of Shareholders. 99.2   Proxy Card. 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.   Scinai Immunotherapeutics Ltd. Date: October 15, 2024   By: